PBLA:NSD-Panbela Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.35

Change

0.00 (0.00)%

Market Cap

USD 1.70M

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 35.29B
ARGX argenx NV ADR

N/A

USD 32.06B
MRNA Moderna Inc

N/A

USD 25.25B
BGNE BeiGene Ltd

N/A

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

N/A

USD 15.95B
SMMT Summit Therapeutics PLC

N/A

USD 15.35B
PCVX Vaxcyte Inc

N/A

USD 14.00B

ETFs Containing PBLA

GREK Global X MSCI Greece ETF 4.88 % 0.59 %

N/A

USD 0.21B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 45,801.64% 97% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 45,801.64% 97% N/A 99% N/A
Trailing 12 Months  
Capital Gain 31,961.07% 96% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 31,961.07% 96% N/A 98% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 67.61% N/A N/A 92% A
Dividend Return 67.61% N/A N/A 92% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 1,968.42% N/A N/A 2% F
Risk Adjusted Return 3.43% N/A N/A 41% F
Market Capitalization 1.70M 2% F 2% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector